Senseonics Holdings, Inc. Reports Third Quarter Financial Results
Rhea-AI Summary
Senseonics (NYSE American: SENS) reported third quarter 2025 results with $8.1M revenue, up 90% YoY, driven by a 160% increase in U.S. new patient starts. Q3 gross profit was $3.5M versus a gross loss in Q3 2024. Net loss narrowed to $19.5M ($0.43/share) from $24.0M a year earlier. Management completed a 1-for-20 reverse stock split (approx. 41M shares outstanding) and plans to move listing to Nasdaq Global Market on Nov 17, 2025. Full-year 2025 revenue outlook is ~$35M, with expected 2025 gross margins of 35–40% and ~$60M cash used in operations.
Positive
- Revenue $8.1M in Q3 (+90% YoY)
- U.S. revenue $6.4M in Q3
- Gross profit $3.5M in Q3 vs $(4.1)M prior year
- U.S. new patient starts +160% YoY
- Full-year 2025 revenue guidance approximately $35M
- 2025 gross margin guidance 35%–40%
Negative
- Net loss of $19.5M in Q3 2025
- SG&A increased by $7.0M to $15.3M in Q3
- R&D spend still $7.8M in Q3 despite reductions
- Expected $60M cash used in operations for 2025
- Executed 1-for-20 reverse split, shares ~41M
News Market Reaction 15 Alerts
On the day this news was published, SENS gained 0.60%, reflecting a mild positive market reaction. Argus tracked a trough of -18.6% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $276M at that time.
Data tracked by StockTitan Argus on the day of publication.
Generated Q3 revenue of
Achieved a
Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics
GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2025.
Recent Highlights & Accomplishments:
- Generated revenue of
$8.1 million in the third quarter of 2025, an increase of90% versus the third quarter of 2024, driven by160% new patient growth in the U.S. over prior year - Expanded direct-to-consumer (DTC) marketing to drive awareness and adoption generating record new patient leads in the quarter
- Signed memorandum of understanding with Ascensia Diabetes Care and collaborating with Ascensia to transition commercial responsibility for Eversense back to Senseonics
- Executed a 1-for-20 reverse stock split, bringing the number of outstanding shares of common stock to approximately 41 million shares
- Planned transfer of stock exchange listing to the Nasdaq Global Market from the NYSE American effective at the opening of trading on November 17th
“The third quarter of 2025 was a record setting quarter, highlighted by all-time highs in new patient shipments, insertions and our patient base. Our hybrid DTC and provider commercial approach continues to accelerate awareness, competitiveness, and growth in Eversense 365 with now approximately
Third Quarter 2025 Results:
Total revenue for the third quarter of 2025 was
Third quarter 2025 gross profit was
Third quarter 2025 research and development expenses decreased by
Third quarter 2025 selling, general and administrative expenses increased by
Net loss was
Total share count, following the 1:20 reverse stock split effected on October 17, 2025, is approximately 41 million shares, which excludes approximately 4.2 million additional shares issuable upon exercise of pre-funded warrants.
Full Year 2025 Financial Outlook
Senseonics expects full-year 2025 global net revenue to be approximately
Conference Call and Webcast Information:
Company management will host a conference call at 4:30 pm (Eastern Time) today, November 5, 2025, to discuss these financial results and recent business developments. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at this link. Individuals interested in participating in the call via telephone may access the call by dialing +1-800-343-5172 (+1-203-518-9856 for those outside the U.S. or Canada) and referencing Conference ID SENSQ3. A replay of the call can be accessed on Senseonics’ website http://www.senseonics.com under “Investor Relations.”.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue, gross margin, cash flow and global installed customer base projections, and global installed customer base assumptions, under the heading “Full Year 2025 Financial Outlook,” statements regarding plans, timing and success of the commercial launch of the 365-day system, the impact of marketing programs, and the adoption of, access to, or growth of use of Eversense, statements concerning the transition of commercial responsibility for Eversense and onboarding of staff, statements regarding development programs and next generation systems, the future regulatory approval and the potential to commercially launch Eversense 365 outside the U.S., and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the negotiation and transition of the commercial responsibility for Eversense from Ascensia and the establishment of those functions at Senseonics, and other commercial initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics’ and its partners’ activities, uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and future reports filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
| Senseonics Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) | ||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 34,458 | $ | 74,597 | ||||
| Restricted cash | 315 | 315 | ||||||
| Short term investments, net | 76,494 | — | ||||||
| Accounts receivable, net | 4,513 | 1,365 | ||||||
| Accounts receivable, net - related parties | 2,683 | 4,921 | ||||||
| Inventory, net | 6,323 | 4,421 | ||||||
| Prepaid expenses and other current assets | 6,489 | 5,819 | ||||||
| Total current assets | 131,275 | 91,438 | ||||||
| Deposits and other assets | 4,634 | 4,926 | ||||||
| Property, equipment and intangible assets, net | 4,015 | 4,074 | ||||||
| Total assets | $ | 139,924 | $ | 100,438 | ||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,932 | $ | 3,205 | ||||
| Accrued expenses and other current liabilities | 11,410 | 13,636 | ||||||
| Accrued expenses and other current liabilities, related parties | 3,732 | 1,870 | ||||||
| Notes payable, current portion, net | — | 20,138 | ||||||
| Total current liabilities | 21,074 | 38,849 | ||||||
| Long-term debt and notes payables, net | 35,266 | 34,703 | ||||||
| Non-current operating lease liabilities | 5,419 | 5,785 | ||||||
| Total liabilities | 61,759 | 79,337 | ||||||
| Preferred stock and additional paid-in-capital, subject to possible redemption: | — | 37,656 | ||||||
| Total temporary equity | — | 37,656 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Common stock, | 41 | 30 | ||||||
| Additional paid-in capital | 1,074,200 | 931,289 | ||||||
| Accumulated other comprehensive income | 88 | — | ||||||
| Accumulated deficit | (996,164 | ) | (947,874 | ) | ||||
| Total stockholders’ equity (deficit) | 78,165 | (16,555 | ) | |||||
| Total liabilities, temporary equity and stockholders’ equity (deficit) | $ | 139,924 | $ | 100,438 | ||||
| Senseonics Holdings, Inc. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue, net | $ | 4,202 | $ | 955 | $ | 9,235 | $ | 2,322 | ||||||||
| Revenue, net - related parties | 3,893 | 3,308 | 11,766 | 11,853 | ||||||||||||
| Total revenue | 8,095 | 4,263 | 21,001 | 14,175 | ||||||||||||
| Cost of sales | 4,627 | 8,314 | 12,907 | 17,593 | ||||||||||||
| Gross profit (loss) | 3,468 | (4,051 | ) | 8,094 | (3,418 | ) | ||||||||||
| Expenses: | ||||||||||||||||
| Research and development expenses | 7,759 | 10,546 | 22,773 | 31,784 | ||||||||||||
| Selling, general and administrative expenses | 15,310 | 8,250 | 32,733 | 25,369 | ||||||||||||
| Operating loss | (19,601 | ) | (22,847 | ) | (47,412 | ) | (60,571 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income | 1,236 | 1,010 | 2,884 | 3,584 | ||||||||||||
| Interest expense | (1,171 | ) | (2,133 | ) | (3,745 | ) | (6,266 | ) | ||||||||
| Gain on change in fair value of derivatives | — | — | — | 102 | ||||||||||||
| Other income (expense) | 6 | (6 | ) | (17 | ) | 11 | ||||||||||
| Total other income (expense), net | 71 | (1,129 | ) | (878 | ) | (2,569 | ) | |||||||||
| Net Loss | (19,530 | ) | (23,976 | ) | (48,290 | ) | (63,140 | ) | ||||||||
| Other comprehensive income | ||||||||||||||||
| Unrealized gain on marketable securities | 65 | 41 | 88 | 45 | ||||||||||||
| Other comprehensive gain | 65 | 41 | 88 | 45 | ||||||||||||
| Total comprehensive loss | $ | (19,465 | ) | $ | (23,935 | ) | $ | (48,202 | ) | $ | (63,095 | ) | ||||
| Basic net loss per common share | $ | (0.43 | ) | $ | (0.77 | ) | $ | (1.19 | ) | $ | (2.05 | ) | ||||
| Basic weighted-average shares outstanding | 44,953,694 | 31,044,897 | 40,554,943 | 30,868,515 | ||||||||||||
| Diluted net loss per common share | $ | (0.43 | ) | $ | (0.77 | ) | $ | (1.19 | ) | $ | (2.05 | ) | ||||
| Diluted weighted-average shares outstanding | 44,953,694 | 31,044,897 | 40,554,943 | 30,868,515 | ||||||||||||
FAQ
What were Senseonics' Q3 2025 revenue and YoY growth (SENS)?
How did Senseonics' U.S. performance change in Q3 2025 (SENS)?
What is Senseonics' full-year 2025 revenue outlook (SENS)?
What guidance did Senseonics give for 2025 gross margins and cash use (SENS)?
Did Senseonics take any corporate actions affecting share count (SENS)?
When will Senseonics move its exchange listing and what is the date (SENS)?
